beeldscherm schreef op 28 november 2018 11:33:
September 2018,
Express Scripts Will Exclude
Some HAE, HIV, Factor Products
With 48 new exclusions on its
2019 National Preferred Formulary
(NPF), Express Scripts Holding Co. is
getting more aggressive in its attempt
to broaden access to pharmaceuticals
and bring value to its clients. But some
industry stakeholders are questioning
its strategy of excluding more specialty
drugs, including some for rare conditions,
as well as a low-cost pangenomic
hepatitis C medication.
The new exclusions are on top of
the 196 drugs Express Scripts already is
excluding in 2018. In 2019, the NPF
will cover more than 25 million lives
and will include 3,886 medications.
The PBM estimates that it will save
$3.2 billion. Those plans that have
continuously used the NPF since Express
Scripts introduced it in 2014 will
save $10.6 billion total through next
year, projects the company.
Among the new exclusions are the
following:
? Novartis Pharmaceuticals Corp.’s
multiple sclerosis drug Extavia (interferon
beta-1b);
? Four factor VIII recombinant
products for hemophilia: Eloctate
from Bioverativ, a Sanofi company;
Shire US Inc.’s Recombinate; and Pfizer
Inc.’s Xyntha and Xyntha Solofuse;
? AbbVie Inc.’s hepatitis C medication
Mavyret (glecaprevir/pibrentasvir);
? CSL Behring LLC’s Berinert (C1
esterase inhibitor, human), indicated
for the treatment of acute abdominal,
facial or laryngeal hereditary angioedema
(HAE) attacks in adult and pediatric
patients; and
? Gilead Sciences, Inc.’s HIV drug
Atripla (efavirenz/emtricitabine/tenofovir
disoproxil fumarate).
wat is dat toch met Ruconest..... hahahahahaha
het Monitorvuur dooft langzaam..hahahahahahaa
ps Exclude = uitsluiten !!